Novel Therapeutic For Treating Brain Injury (Case 2118)

Principal Investigator:


John Marshall, Ph.D.
Professor of Medical Science

Brown University

Providence, RI


Brief Description:


The technology is a novel therapeutic for treating brain injuries, particularly those resulting from stroke, traumatic brain injury (TBI), and spinal cord injury (SCI). The technology has been tested in cell culture and rats, and preliminary data have been collected from human patients diagnosed with stroke, TBI, and SCI who have been administered the technology. Brain injuries affect populations worldwide. According to the WHO, 15 million people worldwide suffer from stroke each year. Of these, 5 million die and another 5 million are often permanently disabled. As of late 2016, there exists no FDA-approved therapeutic treatment for TBI, and this technology would fill this unmet need.


The technology is part of the greater brain injury therapeutics market. As a therapeutic for stroke, this technology is part of the global stroke diagnostics and therapeutics market which was estimated to be worth $21.5 billion USD in 2015 and is forecasted to grow to $31.0 billion USD in 2021 at a CAGR of approximately 7.0% from 2015-2021. Key participants in the stroke diagnostics and therapeutics market include Abbott Laboratories, Boston Scientific Corporation, GE Healthcare, Medtronic Plc, Merck & Co. Inc, and Siemens AG.  This technology may also be useful in treating TBI, and as of late 2016, there exists no FDA-approved therapeutic treatment for TBI; this may open the door for this technology to become a first-of-its-kind therapeutic for TBI and to occupy 100% of the market share for FDA-approved TBI therapeutics. As a therapeutic for brain injury from SCI, this technology may also carve out a part of the SCI therapeutics market. Estimates suggest that in the United States alone, approximately $18 billion USD is spent each year on treating SCI. Potential customers for this technology include pharmaceutical and biotechnology companies, hospitals, sports medicine professionals and practitioners, the military, urgent care clinics, veterinarians, and biomedical researchers.


This technology exhibits several potential advantages versus other technologies used to treat stroke, TBI, and SCI. This technology is advantageous over existing brain injury therapeutics in that it has a relatively low effective dosing, readily crosses the cell membrane of neurons, targets the mitochondria, and has a crucial half-life which provides the patient a post-trauma, protective window of 3-4 hours. There exists a strong potential for this technology to become one of the first, FDA-approved treatments for TBI and to carve out a unique market niche in the global stroke therapeutics and global SCI therapeutics markets as well.




US patent application 14/391,293 is pending.
US patent application 15/393,720 is pending.

Corresponding foreign applications are pending.


Patent Information:
For Information, Contact:
Margaret Shabashevich,
Manager of Operations
Office of Industry Engagement & Commercial Venturing
Brown University
John Marshall
Dennis Goebel
Maik Huttemann
© 2020. All Rights Reserved. Powered by Inteum